{"id":"NCT00660010","sponsor":"Abbott","briefTitle":"Study of Lupron Depot In The Treatment of Central Precocious Puberty","officialTitle":"Study of Lupron Depot In The Treatment of Central Precocious Puberty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1991-01","primaryCompletion":"2009-04","completion":"2009-04","firstPosted":"2008-04-17","resultsPosted":"2010-07-20","lastUpdate":"2011-04-12"},"enrollment":55,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Puberty, Precocious"],"interventions":[{"type":"DRUG","name":"Lupron (leuprolide acetate)","otherNames":["Lupron"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after therapy is discontinued.","primaryOutcome":{"measure":"Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)","timeFrame":"Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit","effectByArm":[{"arm":"Leuprolide Acetate 1 Month Depot","deltaMin":81.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":2},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":["21860633"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":55},"commonTop":["Pharyngitis","Headache","Flu syndrome","Rash","Cough increased"]}}